Does irregular or absent ovulation in perimenopause destabilize the endometrium and cause spotting?

The perimenopausal transition is defined by a progressive decline in ovarian reserve and increased variability in the hypothalamic-pituitary-ovarian (HPO) axis. This physiological shift frequently results in erratic follicular development and anovulatory cycles, creating a hormonal environment characterized by asynchronous estrogen and progesterone exposure.

Clinical evidence

Irregular or absent ovulation is a hallmark of perimenopause, directly leading to a state of "unopposed estrogen." In a healthy ovulatory cycle, the corpus luteum produces progesterone to balance the proliferative effects of estrogen. In perimenopause, however, follicles may produce significant estradiol without subsequent ovulation, leaving the endometrium without the necessary progesterone to induce a stable secretory phase. This hormonal mismatch is classified by major clinical guidelines, including the FIGO PALM-COEIN system, as AUB-O (ovulatory dysfunction) or AUB-E (endometrial), which are primary drivers of spotting and heavy bleeding in women in their 40s.

Mechanistic explanations

The destabilization of the endometrium occurs through specific molecular and structural pathways:

• Extracellular Matrix (ECM) Degradation: Progesterone normally stabilizes the endometrial stroma by inhibiting matrix metalloproteinases (MMPs). When progesterone levels are insufficient, there is a marked increase in MMP-1, MMP-3, and MMP-9 activity. These enzymes degrade the ECM, leading to focal tissue breakdown and irregular shedding.
• Fragile Angiogenesis: Unopposed estrogen promotes continuous proliferation and the expression of Vascular Endothelial Growth Factor (VEGF). This results in the development of immature, fragile microvasculature with high CD34+ expression. These unstable vessels are highly susceptible to rupture, manifesting clinically as spotting or metrorrhagia.
• Loss of Hemostatic Factors: Progesterone withdrawal or absence reduces the upregulation of tissue factor (TF) and plasminogen activator inhibitor 1 (PAI-1), which are critical for maintaining endometrial hemostasis. Without these factors, the uterine lining cannot maintain structural integrity, leading to asynchronous, patchy shedding rather than the coordinated breakdown seen in a normal menstrual cycle.

Bottom line

Strong clinical and mechanistic evidence supports the claim that irregular ovulation in perimenopause creates a hormonal asynchrony that destabilizes the uterine lining. This imbalance—primarily characterized by a lack of progesterone to oppose estrogen—triggers matrix degradation and fragile blood vessel formation, directly resulting in abnormal uterine bleeding and spotting.